Carlo Pincelli

Carlo Pincelli

Company: PinCell

Job title: Chief Medical Officer


Disease Modification in Dermatology: A Novel, First in Class Targeted Therapy for the Non-Immunosuppressive Treatment of Pemphigus & Stevens-Johnson/Toxic Epidermal Necrolysis syndrome 1:00 pm

Development of a human monoclonal antibody against Fas ligand (PC111) that plays a major role in the pathogenesis of pemphigus and Stevens-Johnson/Toxic Epidermal Necrolysis syndrome Sharing recent data demonstrating targeted therapy, that acts downstream of the immune system, highly differentiates from currently used potent immunosuppressors, with a good safety profile, meeting patients’ satisfaction PC111 will…Read more

day: Day One

A Hanson Wade Group Company

© Copyright 2024 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Eastcastle House, 27/28 Eastcastle Street, London, W1W 8DH.